ASH Spotlight: Visit IsoPlexis at Booth 507 to Learn More About How Single-Cell Functional Analysis is Advancing Hematology Research

IsoPlexis will be attending the 64th annual meeting of the American Society of Hematology (ASH), the world’s largest professional society serving both clinicians and scientists around the world who are looking to conquer blood diseases. From December 10th to the 13th  in New Orleans, this conference will feature groundbreaking presentations and poster sessions focused on basic and clinical hematology research.

IsoPlexis will be exhibiting at ASH in booth #507 to meet with attendees and discuss how single-cell proteomics can advance hematology research. Throughout the conference, attendees will have the unique opportunity to interact with the IsoSpark, IsoPlexis’ benchtop instrument for functional proteomic analysis at the IsoPlexis booth, allowing attendees to experience first-hand how the IsoSpark’s streamlined automation generates functional proteomic data in both single-cell and bulk samples without the tedious steps of a traditional assay. Attendees are encouraged to stop by to interact with the IsoSpark benchtop instrument and see a short demo to show how IsoPlexis’ technology can be integrated into their own research projects.

Using Single-Cell Proteomics to Improve Outcomes in Hematology

IsoPlexis’ single-cell functional analysis has already been used in a variety of studies to investigate mechanisms of progression in hematological malignancies and improve therapies. In a recent study published in Blood, ASH’s premier journal for blood disease research, researchers looked to IsoPlexis’ single-cell functional analysis to guide development of CAR-T products generated by a novel gene editing technique for the treatment of T cell acute lymphoblastic leukemia (T-ALL). By comparing the number of polyfunctional cells, or those cells that secrete two or more cytokines and whose frequency has been associated with clinical response, researchers compared two allogeneic CAR-T products with different gene edits to determine which would be most potent. Using IsoPlexis’ Single-Cell Secretome platform, researchers were able to identify the most potent early-stage CAR-T products for further in vivo testing.

In addition to cell therapy development, IsoPlexis’ unique single-cell metrics can also help to predict therapeutic response. In a paper recently published in Science Advances, researchers used single-cell functional analysis to identify biomarkers of CAR-T response and CD19-positive relapse in ALL. By assessing functional secretions of individual cells using IsoPlexis’ Single-Cell Secretome platform, researchers were able to identify specific cytokine profiles secreted by cells from complete responders and those who relapsed. The signal intensity from the cytokines and frequency of cells secreting them were combined to create a measure that was predictive of clinical response, identifying a biomarker that can be used to predict long-term response.

How IsoPlexis’ Functional Proteomics is Driving Hematology Research

IsoPlexis’ single-cell functional proteomics has been used to generate actionable insights into novel cell therapies, evaluate the efficacy of treatments for blood diseases, and understand cellular mechanisms that drive therapeutic response and relapse. With an intuitive interface and effortless automation, researchers can use IsoPlexis technology to generate key insights into how novel therapies affect immune cell function and identify crucial drivers of immune response against some of the most complex diseases.

Visit us at ASH Booth #507 to interact with our innovative platform and learn more about how IsoPlexis’ single-cell functional analysis can advance your research.

Share This Article
Subscribe to Follow the Data

Weekly email to keep you at the forefront of single-cell & multiplexed proteomics.